Apple defeats bid for new Apple Watch import ban at US trade tribunal 

The ITC, an independent federal agency responsible for investigating unfair trade practices, including patent infringement, and imposing remedies like import bans, has been a central arena for this high-stakes legal battle. Its decisions carry substantial weight, as an import ban can severely disrupt a company’s supply chain and market access in the lucrative U.S. market. For Apple, which relies heavily on international manufacturing and global distribution, an ITC ban presents a particularly acute threat, especially for a flagship product like the Apple Watch, a cornerstone of its growing health and wellness ecosystem.

Masimo, a long-established player in medical monitoring technology, now has the option to appeal the ITC’s decision to the Washington-based U.S. Court of Appeals for the Federal Circuit. This specialized court handles all appeals in patent cases, and its rulings can be definitive in intellectual property disputes. However, the path to overturning an ITC decision at the Federal Circuit is often challenging, requiring a demonstration of legal error or abuse of discretion by the Commission. A Masimo spokesperson declined to comment immediately on the ruling or their potential next steps, indicating the company is likely evaluating its strategic options.

Apple, on the other hand, wasted no time in expressing its satisfaction. "We thank the ITC for its decision, which ensures we can continue to offer this important health feature to our users," an Apple spokesperson stated. The company further asserted, "For more than six years, Masimo has waged a relentless legal campaign against Apple, and nearly all of its claims have been rejected." This statement underscores Apple’s consistent position that Masimo’s actions constitute an aggressive and unfounded legal assault, designed to impede Apple’s innovation in the health technology space rather than protect legitimate intellectual property.

The roots of this bitter legal feud trace back several years, blossoming into a complex web of lawsuits across multiple jurisdictions. Masimo first accused Apple of engaging in a predatory strategy to poach its key employees and illicitly acquire its proprietary pulse oximetry technology. This technology, crucial for non-invasively measuring blood oxygen saturation levels, became a marquee feature for Apple Watch models starting with Series 6 in 2020, positioning the device as a serious contender in personal health monitoring. Masimo, with decades of expertise in medical-grade pulse oximetry, viewed Apple’s entry into this field as a direct infringement and an unfair competitive maneuver.

The dispute escalated dramatically in December 2023 when the ITC initially ruled in favor of Masimo, finding that certain Apple Watch models (Series 9 and Ultra 2) did indeed infringe Masimo’s patents. This ruling led to a temporary but impactful import ban on the affected smartwatches during the critical holiday shopping season. While President Joe Biden’s administration opted not to veto the ban, Apple swiftly implemented a workaround: it removed the blood-oxygen reading functionality from its watches sold in the U.S. market to comply with the ITC order and avoid a prolonged sales disruption. This move, though temporary, highlighted the significant commercial stakes involved and Apple’s determination to keep its popular product line available.

However, Apple’s strategy extended beyond simply removing the feature. The company subsequently redesigned the blood-oxygen reading technology within its watches and sought approval from U.S. Customs and Border Protection (CBP) to reintroduce an updated version. In August 2023, CBP approved Apple’s redesigned watches, allowing them to resume imports with the modified blood-oxygen feature. The key technical and legal distinction in the redesigned version lies in how the health data is presented and processed. While Apple’s original implementation displayed blood-oxygen data directly on the watch face, the updated version transmits this data to associated Apple devices, such as an iPhone, for display and analysis, rather than rendering it on the watch itself. This subtle but critical change was ostensibly designed to circumvent the specific patent claims that Masimo had asserted, which Apple argued pertained to the display of the data on the watch.

Masimo, however, was not appeased by Apple’s redesign and the CBP’s approval. Viewing it as an inadequate circumvention, Masimo separately sued CBP over its decision to approve the redesigned watches, arguing that the modifications were insufficient to avoid infringement. This legal action against a federal agency further illustrates the depth of Masimo’s commitment to protecting its intellectual property and its belief that Apple’s actions constitute a continued violation.

Beyond the ITC and CBP battles, the conflict rages on in other significant legal venues. Masimo has also filed a separate lawsuit against Apple in California federal court, alleging broader patent infringement and trade-secret theft. This federal court case encompasses claims that go beyond import bans, seeking monetary damages and potentially broader injunctive relief. In a notable development in November of last year, Masimo secured a significant victory in this federal court case, winning a $634 million verdict against Apple in a patent trial. This substantial monetary award underscored the jury’s finding of infringement and the perceived value of Masimo’s intellectual property. However, Apple has stated its intention to appeal this verdict, setting the stage for further legal proceedings that could take years to resolve.

The multi-front legal war between Apple and Masimo highlights a growing trend of intense intellectual property disputes as major technology companies venture deeper into the highly regulated and patent-rich medical device sector. Wearable technology, particularly smartwatches, has rapidly evolved from lifestyle gadgets to sophisticated health monitoring devices, capable of tracking heart rate, ECG, blood oxygen, and even early signs of serious health conditions. This convergence of consumer electronics and medical technology naturally leads to clashes between established medtech firms, like Masimo, with extensive patent portfolios and regulatory experience, and innovative tech giants, like Apple, with vast resources and a disruptive approach.

Legal experts often point out that patent litigation in the tech and medical fields is notoriously complex, expensive, and time-consuming. Cases can hinge on intricate technical details, the precise wording of patent claims, and varying interpretations of patent law across different courts. The ITC, for example, focuses primarily on import-related infringements, while federal courts address broader infringement claims, trade secret theft, and award monetary damages. This necessitates a multi-pronged legal strategy for companies engaged in such disputes.

From Apple’s perspective, securing the ability to continue offering blood-oxygen monitoring is crucial for its long-term health strategy. The company has consistently emphasized the Apple Watch’s role in empowering users with actionable health insights and promoting preventative care. Removing or permanently altering a key feature like blood-oxygen sensing could diminish the product’s appeal and perceived value, especially as competitors like Samsung and Google also integrate advanced health sensors into their wearables. Analysts suggest that maintaining these health features is vital for Apple to differentiate its products and solidify its position in the rapidly expanding digital health market, projected to be worth hundreds of billions in the coming years.

For Masimo, the battle is about protecting its foundational intellectual property and preventing what it views as unfair competition from a much larger entity. The company’s significant investment in research and development over decades has led to a robust portfolio of patents in pulse oximetry and other medical technologies. Allowing a tech giant to allegedly infringe on these patents without significant consequence could set a dangerous precedent for the entire medtech industry. The $634 million verdict in the California federal court case, even under appeal, serves as a powerful validation of Masimo’s claims and the value of its innovation.

Looking ahead, while the ITC’s latest ruling offers a reprieve for Apple regarding immediate import restrictions, the broader legal saga is far from over. Masimo’s appeal to the Federal Circuit and the ongoing federal court case, including Apple’s appeal of the $634 million verdict, ensure that the dispute will continue to unfold. The outcome of these future legal battles will not only determine the financial and commercial fate of specific products but could also shape how intellectual property is protected and contested at the intersection of consumer technology and medical innovation. This protracted legal drama serves as a stark reminder of the intense competition and high stakes involved as technology giants increasingly venture into specialized medical fields, inevitably clashing with established players and their patented innovations.